Anna Vossenkaemper’s research focuses on the mucosal immune system in the gut in healthy individuals and patients with inflammatory bowel disease. In her current project, collaboration with GlaxoSmithKline, she concentrates on intestinal inflammatory disorders and the inhibition of RIP1 and RIP2 kinases as a potential new way of treating these conditions. Anna works in close collaboration with Prof Jo Spencer (characterization of human Peyer's patch B cells) and Dr Andrew Stagg (phenotyping of Peyer's patch dendritic cells). Anna also reviews various journals, incl. 'Clinical & Experimental Immunology', the 'PLOS' journals and 'Annals of Tropical Medicine & Parasitology'. Her work is currently funded by GlaxoSmithKline.